Stay updated on KeyLargo: Pembrolizumab Combo in Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the KeyLargo: Pembrolizumab Combo in Gastric Cancer Clinical Trial page.

Latest updates to the KeyLargo: Pembrolizumab Combo in Gastric Cancer Clinical Trial page
- Check2 days agoChange DetectedAdded a government funding notice banner and a version update to v3.4.1 (removing v3.4.0). These are administrative site changes and do not affect the study content, eligibility, outcomes, or participant information on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check9 days agoChange DetectedAdded a 'Show glossary' option and updated QC-related labels and revision information (e.g., 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', 'Revision: v3.4.0'); older labels/values (e.g., 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', 'Revision: v3.3.4') were replaced.SummaryDifference0.2%

- Check17 days agoNo Change Detected
- Check23 days agoChange DetectedThe page's revision metadata changed from v3.3.3 to v3.3.4; there are no changes to study details or visible content.SummaryDifference0.1%

- Check45 days agoChange DetectedA consolidated Locations section now lists North Carolina and South Carolina locations, replacing the prior North Carolina Locations and South Carolina Locations subsections. The footer now shows Revision: v3.3.3 and the HHS Vulnerability Disclosure link has been removed.SummaryDifference0.3%

- Check67 days agoChange DetectedFooter revision from v3.3.1 to v3.3.2; no changes to study details or trial data.SummaryDifference0.1%

- Check74 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.1. No changes were made to the study details or user-facing content.SummaryDifference0.1%

Stay in the know with updates to KeyLargo: Pembrolizumab Combo in Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KeyLargo: Pembrolizumab Combo in Gastric Cancer Clinical Trial page.